Adverse extrapyramidal effects in four horse given fluphenazine decanoate

Journal of the American Veterinary Medical Association

Volumn 229, Issue 1, 2006, Pages 104-110

  Baird, John D ^a   Arroyo, Luis G ^a   Vengust, Modest ^a,d   McGurrin, M Kimberly J ^a   Rodriguez Palacios, Alexander ^a   Kenney, Daniel G ^a   Aravagiri, Manickam ^b   Maylin, George A ^c  

^a UNIVERSITY OF GUELPH   (Canada)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c Department of Obstetrics Gynecology   (United States)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZATROPINE MESILATE; DIPHENHYDRAMINE; FLUPHENAZINE DECANOATE;

ACUTE KIDNEY FAILURE; AGITATION; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; HEAD MOVEMENT; HORSE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NONHUMAN; RESPIRATORY FAILURE; RESTLESSNESS; STUPOR; SWEATING; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZTROPINE; DIPHENHYDRAMINE; EXTRAPYRAMIDAL TRACTS; FATAL OUTCOME; FEMALE; FLUPHENAZINE; HORSE DISEASES; HORSES; MALE; NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

CONGIOPODIDAE; EQUIDAE; EQUUS CABALLUS;

EID: 33745715011     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.229.1.104     Document Type: Article

References (37)

1. Weese JS, Baird JD, DeLay J, et al. West Nile virus encephalomyelitis in horses in Ontario: 28 cases. Can Vet J 2003;44:469-473.
2. Kauffman VG, Soma L, Divers TJ, et al. Extrapyramidal side effects caused by fluphenazine decanoate in a horse. J Am Vet Med Assoc 1989;195:1128-1130.
3. Brewer BD, Hines MT, Stewart JT, et al. Fluphenazine induced Parkinson-like syndrome in a horse. Equine Vet J 1990;22:136-137.
4. Van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. Br Med J 1999;319:623-626.
5. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Book Co, 2001;485-520.
6. Aravagiri M, Marder SR, Yuwiler A, et al. Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology 1995;13:235-247.
7. Marder SR, van Kammen DP. Dopamine receptor antagonists (typical antipsychotics). In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock's comprehensive textbook of psychiatry. 7th ed. Vol 2. Philadelphia: Lippincott Williams & Wilkins, 2000;2356-2377.
8. Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003;63:493-512.
9. Miller RS, Peterson GM, McLean S, et al. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate. J Clin Pharm Ther 1995;20:55-62.
10. Luo J-P, Hubbard JW, Midha KK. Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil. Pharm Res 1997;14:1079-1084.
11. Dowling PM. Drugs acting on the neurological system and behavior modification. In: Bertone JJ, Horspool LJI, eds. Equine clinical pharmacology. Edinburgh: WB Saunders Co, 2004;145-154.
12. Vivrette S. Drugs acting on the reproductive system. In: Bertone JJ, Horspool LJI, eds. Equine clinical pharmacology. Edinburgh: WB Saunders Co, 2004;177-191.
13. Collaborative Working Group on Clinical Trial Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998;59(suppl 12):23-27.
14. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:29-40.
15. 2 receptors. Proc Natl Acad Sci U S A 2000;97:7673-7675.
16. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002;3:1381-1391.
17. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000;61(suppl 8):5-11.
18. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-76.
19. Friedman JH. Drug-induced Parkinsonism. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. Mount Kisco, NY: Futura Publishing Co, 1992;41-83.
20. Luo J-P, Hubbard JW, Midha KK. Sensitive method for the simultaneous measurement of fluphenazine decanoate and fluphenazine in plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr B Biomed Sci Appl 1997;688:303-308.
21. Adams CE, Fenton MKP, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-299.
22. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, et al. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 1999;156:412-418.
23. Bertone JJ, Horspool LJI. Drugs and dosages for use in equines. In: Bertone JJ, Horspool LJI, eds. Equine clinical pharmacology. Edinburgh: WB Saunders Co, 2004;367-380.
24. Gitlin MJ, Midha KK, Fogelson D, et al. Persistence of fluphenazine in plasma after decanoate withdrawal. J Clin Psychopharmacol 1988;8:53-56.
25. Marder SR, Aravagiri M, Wirshing WC, et al. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. Schizophr Res 2002;53:25-30.
26. Lee A-S. Treatment of drug-induced dystonic reactions. JACEP 1979;8:453-457.
27. Casey DE. Neuroleptic-induced acute dystonia. In: Lang AE, Weiner WJ, eds. Drug-induced movement disorders. Mount Kisco, NY: Futura Publishing Co, 1992;21-40.
28. Cortese L, Pourcher-Bouchard E, Williams R. Assessment and management of antipsychotic-induced adverse events. Can J Psychiatry 1998;43(suppl 1):15S-20S.
29. Teoh L, Allen H, Kowalenko N. Drug-induced extrapyramidal reactions. J Paediatr Child Health 2002;38:95-97.
30. Sharrock AG. Reversal of drug-induced priapism in a gelding by medication. Aust Vet J 1982;58:39-40.
31. Wilson DV, Nickels FA, Williams MA. Pharmacologic treatment of priapism in two horses. J Am Vet Med Assoc 1991;199:1183-1184.
32. Delay J, Pichot P, Lemperiere T, et al. Un neuroleptique majeur non-phenothiazine et non-reserpin, l'haloperidol, dans le traitment des psychoses. Ann Med Psychol (Paris) 1960;118:145-152.
33. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001;72:325-336.
34. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004;22:389-411.
35. Gupta S, Nihalani ND. Neuroleptic malignant syndrome: a primary care perspective. Prim Care Companion J Clin Psychiatry 2004;6:191-194.
36. Aruna AS, Murungi JH. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. Ann Pharmacother 2005;39:1131-1135.
37. Veterinary Ireland. Use of long-acting phenothiazine tranquilizers without veterinary licence in horses. February, 2005. Available at: www.veterinary-ireland.org. Accessed May 27, 2006.